TFA Therapeutics Opens $15M Offshore Private Placement at $2.52/Share
RAJAF filed a Financing and Capital Events on light trading volume (0.3× avg).
Summary
TFA Therapeutics disclosed a Regulation S offshore private placement of up to $15 million at $2.52 per share, with rolling closings and no minimum. Proceeds will fund TFA-01 development and working capital.
Key Events · Financing and Capital Events · RAJAF
-
Offshore Private Placement Launched
On July 20, 2026, the board approved an offering of up to 5,952,381 ordinary shares at $2.52 per share, targeting aggregate proceeds of up to $15 million.
-
Pricing and Dilution
The subscription price of $2.52 represents an approximate 20% discount to the stated reference value of $3.15 per share, based on a $350 million equity valuation and 111,120,000 outstanding shares.
-
Rolling Closings, No Minimum
There is no minimum subscription amount, and the offering will close in one or more rolling closings as subscriptions are accepted; it remains open as of the report date.
-
Use of Proceeds
Net proceeds will fund TFA-01 development, including CMC, nonclinical safety and toxicology, clinical and regulatory activities, plus working capital and capital-markets readiness.
Analysis · RAJAF · Life Sciences
An offshore private placement of up to $15 million at $2.52 per share has been opened by TFA Therapeutics — a 20% discount to the stated $3.15 reference value. The structure features rolling closings and no minimum, allowing the company to draw capital as subscriptions arrive. Proceeds are earmarked for advancing TFA-01 through CMC, nonclinical safety, and clinical/regulatory work. While the placement is dilutive to existing holders, it provides runway for a development-stage biotech with no approved products. The pricing reference of $350 million equity valuation on 111.12 million shares is disclosed as a commercial reference only, not an independent valuation.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.5% of the 1882 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.18%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RAJAF was trading at $5.20 on OTC in the Life Sciences sector, with a market capitalization of approximately $577.8M. The 52-week trading range was $0.04 to $10.56. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.